Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome

Summary

Platelet-derived microparticles (PDMPs), a procoagulant factor, are reportedly elevated in type 2 diabetes mellitus and acute coronary syndrome. The metabolic syndrome (MS) is strongly associated with cardio- and cerebrovascular disease-related atherothrombotic events. To clarify the level, distribution and correlates of PDMPs with special reference to MS, we conducted a cross-sectional study of 467 healthy Japanese volunteers without signs, symptoms, or a history of cardio- or cerebrovascular disease. They were 211 men and 256 women (median age 39 and 35 years, respectively). Using an ELISA kit and monoclonal antibodies against CD42b and CD42a (glycoprotein Ib and IX) we assayed the PDMP levels. Total cholesterol, low-density and high-density lipoprotein cholesterol, remnant cholesterol, triglycerides, C-reactive protein, and traditional cardiovascular risk factors were also recorded. There was a significant difference in the level of PDMPs between men and women. The median value and the interquartile range of PDMPs was 8.3 IU/ml and 6.2 – 10.5 IU/ml and 6.8 IU/ml and 5.2 – 8.6 IU/ml, respectively, in men and women. PDMPs were significantly associated with MS criteria in men (p<0.001) and women (p=0.040). Logistic regression analysis revealed a significant odds ratio of 3.9 [95% confidence interval (CI): 1.4–10.5] in men and of 4.2 [95% CI: 1.6–10.7] in the entire study population. Our results suggest that PDMPs identified by glycoprotein CD42b and CD42a are positively associated with MS.

Keywords

Atherothrombosis - platelet-derived microparticle - metabolic syndrome

• References

• 1 Miyazaki Y, Nomura S, Miyake T. et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant-containing microparticles. Blood 1996; 88: 3456-3464.
• 2 Reininger AJ, Heijnen HFG, Schumann H. et al. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 2006; 107: 3537-3545.
• 3 Ray DM, Spinelli SL, Pollock SJ. et al. Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost 2008; 99: 86-95.
• 4 Sinauridze EI, Kireev DA, Popenko NY. et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425-434.
• 5 Henn V, Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
• 6 Nomura S. Function and clinical significance of platelet-derived microparticles. Int J Hematol 2001; 74: 397-404.
• 7 Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 1999; 99: 2852-2854.
• 8 Yamazaki M, Uchiyama S, Xiong Y. et al. Effect of remnant-like particles on shear-induced platelet activation and its inhibition by antiplatelet agents. Thromb Res 2005; 115: 211-218.
• 9 Nomura S, Suzuki M, Katsura K. et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 1995; 116: 235-240.
• 10 Nomura S, Uehata S, Saito S. et al. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost 2003; 89: 506-512.
• 11 Namba M, Tanaka A, Shimada K. et al. Circulating platelet-derived microparticles are associated with atherothrombotic events: A marker for vulnerable blood. Arterioscler Thromb Vasc Biol 2007; 27: 255-256.
• 12 Vinik AI, Erbas T, Park TS. et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-1485.
• 13 Diamant M, Tushuizen ME, Sturk A. et al. Cellular microparticles: New players in the field of vascular disease?. Eur J Clin Invest 2004; 34: 392-401.
• 14 Nomura S, Tandon NN, Nakamura T. et al. High-shear-stress-induced activation of platelets and micro-particles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-287.
• 15 Mause SF, von Hundelshausen P, Zernecke A. et al. Platelet microparticles: A transcellular delivery system for RANTES promoting monocyte recruitment on en-dothelium. Arterioscler Thromb Vasc Biol 2005; 25: 1512-1518.
• 16 Arteaga RB, Chirinos JA, Soriano AO. et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 2006; 98: 70-74.
• 17 Ogura H, Kawasaki T, Tanaka H. et al. Activated platelets enhance microparticle formation and platelet-leucocyte interaction in severe trauma and sepsis. J Trauma 2001; 50: 801-809.
• 18 Freyssinet JM. Cellular microparticles: What are they bad or good for?. J Thromb Haemost 2003; 01: 1655-1662.
• 19 Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 2006; 119: 812-819.
• 20 Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: An appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Amer 2004; 33: 431-453.
• 21 Wiberg B, Sundstrom J, Arnlov JT. et al. Metabolic risk factors for stroke and transient ischemic attacks in middle-aged men: A community-based study with long-term follow-up. Stroke 2006; 37: 2898-2903.
• 22 Diamant M, Tushuizen ME. The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD. Curr Diab Rep 2006; 06: 279-286.
• 23 Lee YJ, Jy W, Horstman LL. et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 1993; 72: 295-304.
• 24 Ishikawa S, Kayaba K, Gotoh T. et al. Metabolic syndrome and C-reactive protein in the general population: JMS Cohort Study. Circ J 2007; 71: 26-31.
• 25 Satoh A, Adachi H, Tsuruta M. et al. High plasma level of remnant-like particle cholesterol in the metabolic syndrome. Diabetes Care 2005; 28: 2514-2518.
• 26 Esposito K, Ciotola M, Giugliano D. Pioglitazone reduces endothelial microparticles in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 1926.
• 27 Chironi G, Simon A, Hugel B. et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol 2006; 26: 2775-2780.
• 28 Diamant M, Nieuwland R, Pablo RF. et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-2447.
• 29 Vidal C, Spaulding C, Picard F. et al. Flow cytometry detection of platelet procoagulant activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost 2001; 86: 784-790.
• 30 Osumi K, Ozeki Y, Saito S. et al. Development and assessment of enzyme immunoassay for platelet-derived microparticles. Thromb Haemost 2001; 85: 326-330.
• 31 Kanatani K, Nomura S. A method for measurement of platelet-derived microparticles. Jpn J Thromb Hemost 2007; 18: 653-659.
• 32 Nomura S, Kanazawa S, Fukuhara S. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens 2002; 16: 539-547.
• 33 Nomura S, Shouzu A, Omoto S. et al. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2005; 115: 277-285.
• 34 Nomura S, Shouzu A, Omoto S. et al. Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thrombolysis 2004; 18: 177-185.
• 35 Expert Panel on Detection , Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,And Treatmentof High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.
• 36 Grundy SM, Cleeman JI, Daniels SR. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
• 37 Miyauchi K, Kayahara N, Mori H. Development of homogeneous assay for measuring remnant-like particles of cholesterol in serum. Amer Assn Clin Chem 2005; 51: A129.
• 38 Whicher J, Rifai N, Biasucci LM. Markers of the acute phase response in cardiovascular disease. An update. Clin Chem Lab Med 2001; 39: 1054-1064.
• 39 Holme PA, Orvim U, Hamers MJ. et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with severe stenosis. Arterioscler Thromb Vasc Biol 1997; 17: 646-653.
• 40 Pamuk GE, Vural O, Turgut B. et al. Increased platelet activation markers in rheumatoid arthritis: Are they related with subclinical atherosclerosis?. Platelets 2007; 23: 1-9.
• 41 van der Zee PM, Birü E, Ko Y. et al. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem 2006; 52: 657-664.
• 42 Zhao XM, Wu YP, de Groot PG. Suppressing platelet microparticle formation by antibodies against platelet glycoprotein GPIb. Thromb Haemost 2007; 98: 908.
• 43 Straub A, Breuer M, Wendel HP. et al. Critical temperature ranges of hypothermia-induced platelet activation: Possible implications for cooling patients in cardiac surgery. Thromb Haemost 2007; 97: 608-616.
• 44 Weber A, Köppen HO, Schrör K. Platelet-derived microparticles stimulate coronary artery smooth muscle cell mitogenesis by a PDGF-independent mechanism. Thromb Res 2000; 98: 461-466.